Foghorn Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Foghorn Therapeutics's estimated annual revenue is currently $22.9M per year.
- Foghorn Therapeutics received $50.0M in venture funding in March 2018.
- Foghorn Therapeutics's estimated revenue per employee is $141,605
- Foghorn Therapeutics's total funding is $111M.
Employee Data
- Foghorn Therapeutics has 162 Employees.
- Foghorn Therapeutics grew their employee count by -2% last year.
Foghorn Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CMO | Reveal Email/Phone |
2 | VP, Legal | Reveal Email/Phone |
3 | VP, Protein Degradation Platform | Reveal Email/Phone |
4 | VP, Head Biology | Reveal Email/Phone |
5 | VP, Head Drug Discovery | Reveal Email/Phone |
6 | VP, Corporate Development | Reveal Email/Phone |
7 | VP, Head Chemistry | Reveal Email/Phone |
8 | VP, Head IT | Reveal Email/Phone |
9 | VP, Corporate Affairs, Investor Communications, Chief Staff to the CEO | Reveal Email/Phone |
10 | VP, Program Leadership | Reveal Email/Phone |
Foghorn Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Foghorn Therapeutics?
More than 20,000 genes make us human. Genes control critical aspects of health and disease but what controls our genes A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control(TM) platform, Foghorn will change how genes turn on and off. Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for usand rewrite destiny for millions of people living with disease. With Gene Traffic Control(TM) Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
keywords:N/A
$111M
Total Funding
162
Number of Employees
$22.9M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Foghorn Therapeutics News
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the...
About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined...
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and...
Over the past few years, she has turned down money from pharmaceutical companies so that she could cofound Foghorn Therapeutics, hoping ...
A decade ago, when Cigall Kadoch joined Gerald Crabtree's lab at Stanford University, she was an odd fit: the incoming graduate student was ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.1M | 162 | 11% | N/A |
#2 | $42.7M | 162 | 3% | $300M |
#3 | $31.4M | 162 | 5% | $121M |
#4 | $15M | 162 | 7% | N/A |
#5 | $26M | 163 | 36% | N/A |
Foghorn Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-03-14 | $50.0M | Undisclosed | Flagship Pioneering | Article |